- Coherus retained Oppenheimer & Co. to market and sell legacy biosimilar assets.
Coherus Oncology (CHRS) hired Oppenheimer & Co. to sell its legacy biosimilar assets. Shareholders of record on Sept 30 will receive CVRs that pay out a pro rata share of net proceeds from the sale. Distribution is Oct 7.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.